Navigation Links
Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates
Date:6/18/2012

SAN DIEGO, June 18, 2012 /PRNewswire/ -- Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

"Ambrx's technology has the potential to provide the foundation for a new family of biologic drug conjugates that selectively deliver small molecules to their site of action," said Peter G. Schultz, Ph.D., a scientific founder and board member. "Merck's deep disease area expertise made it the partner of choice in expanding the application of this technology beyond oncology to other important disease areas."

Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize biotherapeutic drug conjugates directed towards a number of pre-specified targets.  Ambrx will receive an upfront payment of $15 million and is eligible to receive milestone payments totaling up to $288 million for successful discovery, development and commercialization of candidates to all pre-specified targets. In addition, Ambrx will receive royalties on any net sales of products resulting from the collaboration.

"Collaborations are an important part of our strategy to develop a portfolio of next generation protein therapeutics that may offer significant benefits to patients," said Richard Murray, Ph.D., senior vice president and head of biologics and vaccines research at Merck. "This agreement will allow us to combine Ambrx's expertise in site-specific protein conjugation chemistry with Merck's expanding antibody capabilities and extensive small molecule resources."

By combining the targeting properties of biologics with the potent therapeutic properties of small molecules, Merck and Ambrx plan to design and optimize new ways to specifically deliver pharmacologically active compounds to their site of action while minimizing the potential for systemic effects.

About AmbrxAmbrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including antibody drug conjugates and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Bristol Myers Squibb, Eli Lilly and Company and several undisclosed companies.  Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.Media Contacts: AmbrxIan Stone (619) 308-6541 David Schull(212) 845-4271


'/>"/>
SOURCE Ambrx Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Goddard collaborates with international partners on MMS instrument
2. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
3. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
6. Computer-designed molecules point to new therapy for cystic fibrosis
7. Bioreactor redesign dramatically improves yield
8. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award
9. Fundamental steps needed now in global redesign of Earth system governance
10. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
11. Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Molecular Devices, LLC, a ... GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. This novel ... and provide visual documentation of monoclonality for use in cell line development. ...
(Date:9/18/2017)... 2017   Montrium , a growing leader in Electronic ... with a groundbreaking non-profit research organization, Multidisciplinary Association for Psychedelic ... MAPS ... PTSD ... Therapy Designation to MDMA for the treatment of Posttraumatic Stress Disorder ...
(Date:9/14/2017)... PA and London UK (PRWEB) , ... September ... ... will gather the most innovative minds in pharma and biotech at the third ... a two-day collaborative conference that brings together the world’s most progressive clinical research ...
(Date:9/14/2017)... ... 14, 2017 , ... AIM Global, the worldwide standards agency for AIDC and ... 2017 Case Study Competition for AIDC. The award is given to those in ... push the adoption of automated data collection systems further. The TRACTUS platform, by ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):